vs
Side-by-side financial comparison of CENTURY CASINOS INC (CNTY) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($177.4M vs $138.0M, roughly 1.3× CENTURY CASINOS INC). Pacira BioSciences, Inc. runs the higher net margin — 1.6% vs -13.0%, a 14.6% gap on every dollar of revenue. On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.0% vs 0.2%). Over the past eight quarters, CENTURY CASINOS INC's revenue compounded faster (0.7% CAGR vs -0.2%).
Century Casinos, Inc. is a gambling company based in Colorado Springs, Colorado.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
CNTY vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $138.0M | $177.4M |
| Net Profit | $-17.9M | $2.9M |
| Gross Margin | — | — |
| Operating Margin | 7.6% | 3.9% |
| Net Margin | -13.0% | 1.6% |
| Revenue YoY | 0.2% | 5.0% |
| Net Profit YoY | 80.1% | — |
| EPS (diluted) | $-0.62 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $138.0M | $196.9M | ||
| Q3 25 | $153.7M | $179.5M | ||
| Q2 25 | $150.8M | $181.1M | ||
| Q1 25 | $130.4M | $168.9M | ||
| Q4 24 | $137.8M | $187.3M | ||
| Q3 24 | $155.7M | $168.6M | ||
| Q2 24 | $146.4M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $-17.9M | — | ||
| Q3 25 | $-10.5M | $5.4M | ||
| Q2 25 | $-12.3M | $-4.8M | ||
| Q1 25 | $-20.6M | $4.8M | ||
| Q4 24 | $-90.3M | — | ||
| Q3 24 | $-8.1M | $-143.5M | ||
| Q2 24 | $-41.6M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | 7.6% | 1.2% | ||
| Q3 25 | 11.1% | 3.5% | ||
| Q2 25 | 11.0% | 4.7% | ||
| Q1 25 | 5.5% | 1.2% | ||
| Q4 24 | -45.5% | 13.2% | ||
| Q3 24 | 11.5% | -82.8% | ||
| Q2 24 | 9.7% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | -13.0% | — | ||
| Q3 25 | -6.9% | 3.0% | ||
| Q2 25 | -8.2% | -2.7% | ||
| Q1 25 | -15.8% | 2.8% | ||
| Q4 24 | -65.6% | — | ||
| Q3 24 | -5.2% | -85.1% | ||
| Q2 24 | -28.4% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $-0.62 | $0.05 | ||
| Q3 25 | $-0.35 | $0.12 | ||
| Q2 25 | $-0.40 | $-0.11 | ||
| Q1 25 | $-0.67 | $0.10 | ||
| Q4 24 | $-2.95 | $0.38 | ||
| Q3 24 | $-0.26 | $-3.11 | ||
| Q2 24 | $-1.36 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $68.9M | $144.3M |
| Total DebtLower is stronger | $328.9M | — |
| Stockholders' EquityBook value | $-97.7M | $653.9M |
| Total Assets | $1.1B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $68.9M | $238.4M | ||
| Q3 25 | $77.7M | $246.3M | ||
| Q2 25 | $85.5M | $445.9M | ||
| Q1 25 | $84.7M | $493.6M | ||
| Q4 24 | $98.8M | $484.6M | ||
| Q3 24 | $118.8M | $453.8M | ||
| Q2 24 | $123.2M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | $328.9M | $372.2M | ||
| Q3 25 | $329.3M | $376.7M | ||
| Q2 25 | $328.0M | $580.5M | ||
| Q1 25 | $328.8M | $583.4M | ||
| Q4 24 | $328.2M | $585.3M | ||
| Q3 24 | $327.5M | — | ||
| Q2 24 | $328.8M | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $-97.7M | $693.1M | ||
| Q3 25 | $-78.6M | $727.2M | ||
| Q2 25 | $-66.9M | $757.8M | ||
| Q1 25 | $-54.3M | $798.5M | ||
| Q4 24 | $-34.7M | $778.3M | ||
| Q3 24 | $56.8M | $749.6M | ||
| Q2 24 | $64.6M | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $1.1B | $1.3B | ||
| Q3 25 | $1.2B | $1.3B | ||
| Q2 25 | $1.2B | $1.5B | ||
| Q1 25 | $1.2B | $1.6B | ||
| Q4 24 | $1.2B | $1.6B | ||
| Q3 24 | $1.3B | $1.5B | ||
| Q2 24 | $1.3B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | 5.77× | — | ||
| Q2 24 | 5.09× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-114.0K | — |
| Free Cash FlowOCF − Capex | $-4.7M | — |
| FCF MarginFCF / Revenue | -3.4% | — |
| Capex IntensityCapex / Revenue | 3.3% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-15.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-114.0K | $43.7M | ||
| Q3 25 | $144.0K | $60.8M | ||
| Q2 25 | $11.3M | $12.0M | ||
| Q1 25 | $-4.6M | $35.5M | ||
| Q4 24 | $-2.3M | $33.1M | ||
| Q3 24 | $7.4M | $53.9M | ||
| Q2 24 | $3.0M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $-4.7M | $43.5M | ||
| Q3 25 | $-4.7M | $57.0M | ||
| Q2 25 | $5.5M | $9.3M | ||
| Q1 25 | $-11.3M | $26.9M | ||
| Q4 24 | $-16.9M | $31.0M | ||
| Q3 24 | $-2.8M | $49.8M | ||
| Q2 24 | $-12.9M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | -3.4% | 22.1% | ||
| Q3 25 | -3.1% | 31.7% | ||
| Q2 25 | 3.6% | 5.1% | ||
| Q1 25 | -8.7% | 15.9% | ||
| Q4 24 | -12.3% | 16.6% | ||
| Q3 24 | -1.8% | 29.6% | ||
| Q2 24 | -8.8% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 3.3% | 0.1% | ||
| Q3 25 | 3.2% | 2.2% | ||
| Q2 25 | 3.9% | 1.5% | ||
| Q1 25 | 5.1% | 5.1% | ||
| Q4 24 | 10.7% | 1.1% | ||
| Q3 24 | 6.6% | 2.4% | ||
| Q2 24 | 10.9% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 11.20× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 7.37× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CNTY
| Gaming | $103.9M | 75% |
| Food And Beverage | $13.2M | 10% |
| Hotel | $10.5M | 8% |
| Other | $5.2M | 4% |
| Pari Mutuel And Sports Betting And Igaming | $5.2M | 4% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
